Jim Heather Sl, Boyd Tim D, Booth-Jones Margaret, Pidala Joseph, Potter Huntington
Moffitt Cancer Center, 12902 Magnolia Drive MRC-PSY, Tampa, FL, USA.
Brain Disord Ther. 2012;1(1). doi: 10.4172/bdt.1000101.
Endogenous Granulocyte Macrophage Colony Stimulating Factor (GMCSF) is released in rheumatoid arthritis patients, who are largely protected from Alzheimer's disease (AD). Introducing exogenous GMCSF into an AD mouse model reduced amyloid deposition by 55% and restored normal cognition. No published studies have examined exogenous GMCSF and cognitive functioning in humans. OBJECTIVES/DESIGN: The goal of the current study was to examine the association between receipt of GMCSF and cognitive functioning in patients receiving colony stimulating factors as part of routine supportive care for hematopoietic cell transplantation (HCT). SETTING AND PARTICIPANTS: Archived neuropsychological data were examined from a longitudinal study of cognitive functioning in 95 patients receiving HCT at the Moffitt Cancer Center. INTERVENTION: Receipt of GMCSF and/or Granulocyte Colony Stimulating Factor (GCSF) was ascertained through patient billing records. MEASUREMENTS: Patients were assessed with a battery of neuropsychological tests prior to transplant and 6 and 12 months post-transplant. RESULTS: Patients treated with GMCSF and GCSF (n=19) showed significantly greater improvement in total neuropsychological functioning (TNP) at 6 months than patients treated with GCSF only (n=76) (p=.04). There was no group difference in TNP at 12 months (p=.24). Improvement in TNP from baseline to 6 months post-HCT was significant in the GMCSF+GCSF group (p=.01) but not the GCSF only group (p=.33). Improvement in TNP from baseline to 12 months post-HCT was significant in both groups (ps<.01). CONCLUSION: Preliminary data from this study of humans receiving colony stimulating factors suggest that receipt of GMCSF+GCSF was associated with greater cognitive improvement than GCSF alone. Randomized controlled trials of the effects of GMCSF on cognitive functioning in humans are warranted and underway to confirm these findings.
内源性粒细胞巨噬细胞集落刺激因子（GMCSF）在类风湿关节炎患者中释放，这些患者在很大程度上可预防阿尔茨海默病（AD）。将外源性GMCSF引入AD小鼠模型可使淀粉样蛋白沉积减少55%并恢复正常认知。尚无已发表的研究探讨外源性GMCSF与人类认知功能的关系。
目的/设计：本研究的目的是探讨接受造血细胞移植（HCT）常规支持治疗的患者接受GMCSF与认知功能之间的关联。
从莫菲特癌症中心对95例接受HCT患者的认知功能进行的纵向研究中检查存档的神经心理学数据。
通过患者计费记录确定是否接受GMCSF和/或粒细胞集落刺激因子（GCSF）。
在移植前以及移植后6个月和12个月，对患者进行一系列神经心理学测试。
接受GMCSF和GCSF治疗的患者（n = 19）在6个月时总体神经心理学功能（TNP）的改善明显大于仅接受GCSF治疗的患者（n = 76）（p = 0.04）。12个月时两组在TNP方面无差异（p = 0.24）。GMCSF + GCSF组从基线到HCT后6个月TNP的改善显著（p = 0.01），而仅接受GCSF组则不显著（p = 0.33）。两组从基线到HCT后12个月TNP均有显著改善（p < 0.01）。
本研究中接受集落刺激因子的人类初步数据表明，接受GMCSF + GCSF比单独接受GCSF与更大的认知改善相关。有必要且正在进行关于GMCSF对人类认知功能影响的随机对照试验以证实这些发现。
